Literature DB >> 16517112

Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up.

P Mhawech-Fauceglia1, G Fischer, A Beck, R T Cheney, F R Herrmann.   

Abstract

AIMS: The study was designed to evaluate Raf1, Aurora-A/STK15 and E-cadherin (E-CD) protein expression and their prognostic value in patients with pTa/pT1 tumours.
MATERIALS AND METHODS: A tissue microarray of 105 pTa, and 141 pT1 tumours was constructed and sections were immunostained with these three antibodies.
RESULTS: There were significant associations between Raf1 overexpression and tumour grade (p = 0.03), between Aurora-A overexpression/alterations of E-CD and tumour grade and stage (p < 0.001 and p < 0.001). In multiple Cox regression analysis, moderate/strong expression of E-CD seemed to be an independent factor in predicting slower tumour progression (p = 0.003) and Aurora-A overexpression (p = 0.022) displays an independent value in predicting tumour recurrences.
CONCLUSION: Evaluation of E-CD and Aurora-A expressions in tissue of patients with pTa/pT1 UC have been proven to be useful in predicting tumours behavior and Raf1 protein expression seemed to have no potential use in this regard.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517112     DOI: 10.1016/j.ejso.2006.01.018

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.

Authors:  Michela de Martino; Shahrokh F Shariat; Sebastian L Hofbauer; Ilaria Lucca; Christopher Taus; Helene G Wiener; Andrea Haitel; Martin Susani; Tobias Klatte
Journal:  World J Urol       Date:  2014-02-23       Impact factor: 4.226

Review 3.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

Review 4.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

5.  Bladder cancer: can we move beyond chemotherapy?

Authors:  Arlene Siefker-Radtke
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 6.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 7.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

8.  Implication of RAF and RKIP genes in urinary bladder cancer.

Authors:  Apostolos Zaravinos; Maria Chatziioannou; George I Lambrou; Ioannis Boulalas; Dimitris Delakas; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

9.  The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Authors:  Ning Zhou; Kamini Singh; Maria C Mir; Yvonne Parker; Daniel Lindner; Robert Dreicer; Jeffrey A Ecsedy; Zhongfa Zhang; Bin T Teh; Alexandru Almasan; Donna E Hansel
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

10.  Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Authors:  Aaron Mobley; Shizhen Zhang; Jolanta Bondaruk; Yan Wang; Tadeusz Majewski; Nancy P Caraway; Li Huang; Einav Shoshan; Guermarie Velazquez-Torres; Giovanni Nitti; Sangkyou Lee; June Goo Lee; Enrique Fuentes-Mattei; Daniel Willis; Li Zhang; Charles C Guo; Hui Yao; Keith Baggerly; Yair Lotan; Seth P Lerner; Colin Dinney; David McConkey; Menashe Bar-Eli; Bogdan Czerniak
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.